A Farnesyltransferase Inhibitor Study

Now enrolling patients with HRAS-mutant HNSCC

The FDA has granted Breakthrough Therapy Designation for tipifarnib for the treatment of patients with recurrent or metastatic HRAS mutant HNSCC with variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy